RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS.

doi:10.1038/s41375-022-01584-3

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS.

Leukemia - 1 Jul 2022

Kaisrlikova Monika, Vesela Jitka, Kundrat David, Votavova Hana, Dostalova Merkerova Michaela, Krejcik Zdenek, Divoky Vladimir, Jedlicka Marek, Fric Jan, Klema Jiri, Mikulenkova Dana, Stastna Markova Marketa, Lauermannova Marie, Mertova Jolana, Soukupova Maaloufova Jacqueline, Jonasova Anna, Cermak Jaroslav, Belickova Monika

Abstract excerpt

Patients with lower-risk myelodysplastic syndromes (LR-MDS) have a generally favorable prognosis; however, a small proportion of cases progress rapidly. This study aimed to define molecular biomarkers predictive of LR-MDS progression and to uncover cellular pathways contributing to malignant transformation. The mutational landscape was analyzed in 214 LR-MDS patients, and at least one mutation was detected in 137...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cell Transformation, Neoplastic

Share to Core Binding Factor Alpha 2 Subunit

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Prognosis

Share to Vascular Tumors and Angiosarcomas

Source

Open in PubMed Open full text

Identifiers

PMID: 35505182
DOI: 10.1038/s41375-022-01584-3
PMCID: PMC9252911

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RUNX1 mutations contribute to the progression of MDS due to disruption of antitumor cellular defense: a study on patients with lower-risk MDS.PMID 35505182Read ↗

Prognostic effect of RUNX1 mutations in myelodysplastic syndromes: a meta-analysis.Semantic proximity Read ↗

Distinct mutation profile and prognostic relevance in patients with hypoplastic myelodysplastic syndromes (h-MDS).Semantic proximity Read ↗

Implications of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome (MDS): future molecular therapeutic directions for MDS.Semantic proximity Read ↗

Incorporation mutational profile might reduce the importance of blast count in prognostication of low-risk myelodysplastic syndromes.Semantic proximity Read ↗

Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia.Semantic proximity Read ↗

Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.Semantic proximity Read ↗

Impact of U2AF1 Pathogenic Variants on Prognosis of Myelodysplastic Neoplasms With RUNX1 Mutation.Semantic proximity Read ↗

Clinical implications of U2AF1 mutation in patients with myelodysplastic syndrome and its stability during disease progression.Semantic proximity Read ↗

Distinct genetic landscapes and their clinical implications in younger and older patients with myelodysplastic syndromes.Semantic proximity Read ↗

SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients With Lower-Risk Myelodysplastic Syndrome.Semantic proximity Read ↗

Therapy for lower-risk MDS.Semantic proximity Read ↗

Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.